Efficacy

Ilumya (Tildrakizumab) Efficacy in Psoriasis

Ilumya, known generically as tildrakizumab, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine that plays a key role in the pathogenesis of psoriasis. By inhibiting IL-23, Ilumya helps to reduce the inflammation and skin cell proliferation associated with psoriasis.

Clinical trials have demonstrated the efficacy of Ilumya in achieving significant skin clearance in patients with plaque psoriasis. In these studies, patients treated with Ilumya showed a marked reduction in the severity of their skin lesions, measured by the Psoriasis Area and Severity Index (PASI). A significant number of patients achieved PASI 75, which indicates a 75% reduction in the PASI score, within 12 weeks of treatment. Furthermore, many patients maintained this level of response with continued treatment.

Sotyktu (Deucravacitinib) Efficacy in Psoriasis

Sotyktu, with the generic name deucravacitinib, is a novel oral medication approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. TYK2 is involved in the signaling pathways of several pro-inflammatory cytokines that contribute to the pathophysiology of psoriasis, including interleukins IL-12, IL-23, and interferon-alpha. By inhibiting TYK2, Sotyktu reduces the inflammatory response that leads to the development of psoriatic plaques.

The efficacy of Sotyktu in the treatment of plaque psoriasis has been evaluated in clinical trials. Patients receiving deucravacitinib exhibited significant improvements in their psoriasis symptoms compared to those receiving placebo. The primary endpoint for these trials was the achievement of PASI 75, and a considerable percentage of patients treated with Sotyktu reached this goal. Notably, the medication demonstrated a rapid onset of action, with some patients observing improvements as early as the first few weeks of treatment. Additionally, the clinical trials indicated that the efficacy of Sotyktu was sustained over a longer duration, with many patients maintaining skin clearance over time.